A Phase 2, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of ISIS 301012 [mipomersen sodium] as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of ISIS 301012 [mipomersen sodium] as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 15 May 2010 Results published in The American journal of cardiology.
    • 25 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2007 Drug named changed from ISIS 301012 to mipomersen sodium (INN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top